Reimagining Pediatric GEP-NET Treatment with LUTATHERA

πρόσθεσε ένα νέο άρθρο Dịch vụ

2025-09-16 10:18:10 -

Novartis’ LUTATHERA (lutetium Lu 177 dotatate) has already been a breakthrough in treating gastroenteropancreatic neuroendocrine tumors (GEP-NETs). With its approval now extended to pediatric patients, Novartis further strengthens its leadership in oncology. While the lutathera cost remains a central discussion point, this expansion underscores the therapy’s value in addressing...

0 Σχόλια 0 Μοιράστηκε 118 Views